GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Rafael Holdings Inc (NYSE:RFL) » Definitions » Sloan Ratio %

Rafael Holdings (Rafael Holdings) Sloan Ratio % : 4.14% (As of Jan. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Rafael Holdings Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Rafael Holdings's Sloan Ratio for the quarter that ended in Jan. 2024 was 4.14%.

As of Jan. 2024, Rafael Holdings has a Sloan Ratio of 4.14%, indicating the company is in the safe zone and there is no funny business with accruals.


Rafael Holdings Sloan Ratio % Historical Data

The historical data trend for Rafael Holdings's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rafael Holdings Sloan Ratio % Chart

Rafael Holdings Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Sloan Ratio %
Get a 7-Day Free Trial 20.88 -3.46 -0.50 -29.40 -12.35

Rafael Holdings Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.43 -4.12 -12.35 3.02 4.14

Competitive Comparison of Rafael Holdings's Sloan Ratio %

For the Real Estate Services subindustry, Rafael Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rafael Holdings's Sloan Ratio % Distribution in the Real Estate Industry

For the Real Estate industry and Real Estate sector, Rafael Holdings's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Rafael Holdings's Sloan Ratio % falls into.



Rafael Holdings Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Rafael Holdings's Sloan Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Sloan Ratio=(Net Income (A: Jul. 2023 )-Cash Flow from Operations (A: Jul. 2023 )
-Cash Flow from Investing (A: Jul. 2023 ))/Total Assets (A: Jul. 2023 )
=(-1.876--10.886
-21.211)/98.829
=-12.35%

Rafael Holdings's Sloan Ratio for the quarter that ended in Jan. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jan. 2024 )
=(2.191--7.424
-5.217)/106.149
=4.14%

Rafael Holdings's Net Income for the trailing twelve months (TTM) ended in Jan. 2024 was -1.437 (Apr. 2023 ) + 1.219 (Jul. 2023 ) + -3.638 (Oct. 2023 ) + 6.047 (Jan. 2024 ) = $2.19 Mil.
Rafael Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jan. 2024 was -1.314 (Apr. 2023 ) + -1.448 (Jul. 2023 ) + -2.133 (Oct. 2023 ) + -2.529 (Jan. 2024 ) = $-7.42 Mil.
Rafael Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jan. 2024 was 7.387 (Apr. 2023 ) + 7.407 (Jul. 2023 ) + -6.786 (Oct. 2023 ) + -2.791 (Jan. 2024 ) = $5.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rafael Holdings  (NYSE:RFL) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jan. 2024, Rafael Holdings has a Sloan Ratio of 4.14%, indicating the company is in the safe zone and there is no funny business with accruals.


Rafael Holdings Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Rafael Holdings's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rafael Holdings (Rafael Holdings) Business Description

Traded in Other Exchanges
N/A
Address
520 Broad Street, Newark, NJ, USA, 07102
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.
Executives
I9 Plus, Llc 10 percent owner 153 BOOTH AVE, ENGLEWOOD NJ 07631
Howard S Jonas director
Mary Margaret Huizinga officer: Chief Devel. & Medical Officer C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Ashok D Marin officer: Chief Legal Officer C/O LIPOSCIENCE, INC., 2500 SUMNER BOULEVARD, RALEIGH NC 27616
Patrick Fabbio officer: Chief Financial Officer 2 PITNEY COURT, BASKING RIDGE NJ 07920
Mark Anthony Mccamish director C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Shannon Thyme Klinger director 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Ameet Mallik officer: CHIEF EXECUTIVE OFFICER C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
William Conkling officer: Chief Commercial Officer C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Rachel Jonas director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Boris C Pasche director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Michael J Weiss director C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
Stephen M Greenberg director C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
David Polinsky officer: Chief Financial Officer 90 BOOTH AVENUE, ENGLEWOOD NJ 07631
Menachem Ash director, officer: President C/O IDT CORPORATION, 520 BROAD STREET, NEWARK NJ 07102

Rafael Holdings (Rafael Holdings) Headlines

From GuruFocus